<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127300">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445028</url>
  </required_header>
  <id_info>
    <org_study_id>WEI-DELIVER</org_study_id>
    <nct_id>NCT01445028</nct_id>
  </id_info>
  <brief_title>Isotretinoin for Proliferative Vitreoretinopathy</brief_title>
  <acronym>DELIVER</acronym>
  <official_title>Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an
      important cause of retinal re-detachment. The purpose of this study is to evaluate the
      effect of oral isotretinoin, which inhibits the growth of cells responsible for
      proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Small retrospective studies have shown isotretinoin to be effective in reducing the rate of
      recurrent retinal detachment in patients with or at high risk for developing PVR. This is a
      prospective study to evaluate a low dose of oral isotretinoin in this regard. There are two
      arms to the study: 1) eyes with recurrent retinal detachment due to existing PVR, and 2)
      eyes with primary detachment and features associated with a high risk of PVR formation.
      Eligible and willing patients will receive a 12-week course of isotretinoin, and will be
      followed for retinal attachment rate, and PVR and/or ERM (epiretinal membrane) formation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of retinal attachment</measure>
    <time_frame>6 months</time_frame>
    <description>We will evaluate all patients for retinal attachment at 3 and 6-months following enrollment in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epiretinal membrane formation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Proliferative Vitreoretinopathy</condition>
  <arm_group>
    <arm_group_label>Primary, high-risk retinal detachment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Recurrent RD associated with PVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Isotretinoin 20mg daily for 12 weeks</description>
    <arm_group_label>Primary, high-risk retinal detachment</arm_group_label>
    <arm_group_label>Recurrent RD associated with PVR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 year-old men or 50-70 year-old, post-menopausal women.

          -  Healthy enough to participate in the study.

          -  Willing and able to consent to participation.

          -  Recurrent PVR-associated RD occurring at least 2 weeks after RD repair or

          -  Primary RD (retinal detachment) associated with one or more high-risk features

        Exclusion Criteria:

          -  History of hypersensitivity to isotretinoin.

          -  Current use of a corticosteroid (excluding topical).

          -  Any history of depression, anorexia, liver or pancreatic disease.

          -  More than one prior surgical RD repair.

          -  Patients with closed funnel retinal detachments.

          -  Patients with chronic retinal detachment, defined as longer than 12 weeks.

          -  Any use an oral retinoid within 6 months.

          -  Systemic chemotherapy within 6 months.

          -  Patients taking supplemental vitamin A.

          -  Corneal opacity sufficient to impair surgical view.

          -  Proliferative diabetic retinopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Kaiser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>September 29, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Richard S. Kaiser</investigator_full_name>
    <investigator_title>Associate Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
